Engineering Specificity and Function of Therapeutic Regulatory T Cells

Area of Science:

• Immunology
• Cell Therapy
• Gene Engineering

Background:

• Adoptive therapy with polyclonal regulatory T cells (Tregs) shows promise in managing autoimmunity and transplantation.
• A key limitation of current Treg therapy is the lack of antigen specificity, which can be crucial for therapeutic potency.
• Naturally occurring antigen-specific Tregs are rare and difficult to isolate.

Purpose of the Study:

• To discuss strategies for generating antigen-specific Tregs to overcome limitations of polyclonal Treg therapy.
• To explore the potential of gene transfer technologies for producing Tregs with defined specificity and function.
• To highlight the implications of Treg lineage plasticity for developing targeted Treg therapies.

Main Methods:

• Utilizing vectors encoding T cell receptors (TCRs) or chimeric antigen receptors (CARs) for gene transfer into Tregs.
• Leveraging established and emerging gene transfer and editing tools.
• Considering the polarization of Tregs into distinct lineages (e.g., Th1, Th2, Th17-like) for targeted therapy.

Main Results:

• Gene transfer platforms can reliably produce Tregs with defined antigen specificity, addressing challenges in isolating natural Treg populations.
• Genetic engineering can enforce stable Treg phenotypes and direct differentiation into specific Treg subsets.
• This approach facilitates the creation of tailor-made, antigen-specific Treg products.

Conclusions:

• Engineered Tregs with defined antigen specificity represent a significant advancement over polyclonal Treg therapy.
• Gene editing and transfer technologies offer powerful tools for developing next-generation Treg cell therapies.
• Tailor-made, antigen-specific Tregs hold great potential for treating immune-mediated diseases with enhanced efficacy and safety.